Table 1.
PDT agents in clinical use or in clinical trialsa.
| Class | PDT agent | Metal | Stage | Excitation (nm) | Area | Cancer type |
|---|---|---|---|---|---|---|
| Protoporphyrin IX precursor | 5-Aminolevulinic acid (Levulan®) | FDA approved | 635 | Global | Skin, brain, oesophagus | |
| Methyl aminolevulinate (Metvix®) | FDA approved | 635 | Skin | |||
| Hexyl 5-aminolevulinate (Hexvix®) | FDA approved | 380–450 (diagnosis) | Bladder | |||
| Porphyrin derivatives | Porfimer sodium (Photofrin®) | FDA approved | 630 | Global | Lung, bladder, oesophagus, bile duct, brain | |
| Photogem | MHRF approved | 660 | Russia | Respiratory and digestive tracts, urogenital | ||
| Chlorin derivatives | Temoporfin (Foscan®) | EMA approved | 652 | EU | Head and neck, bile duct, lung | |
| Ce6-PVP (Fotolon®) | Phase 2 | 660–670 | Germany | Lung | ||
| Radachlorin® | MHRF approved | 662 | Russia | Skin | ||
| Talaporfin sodium (Laserphyrin®) | MHLW approved | 664 | Japan | Lung, brain | ||
| HPPH (Photochlor®) | Phase 2 | 665 | USA | Lung, oral cavity, oesophagus | ||
| Bacteriochlorin derivatives | Redaporfin | Phase 2 | 749 | Portugal | Head and neck | |
| Phthalocyanine derivatives | Silicon phthalocyanine (Pc4) | Phase 1 | 672 | USA | Skin | |
| Metal complex | Padoporfin (TOOKAD®) | Pd | Terminated | 763 | EU | Prostate |
| Padeliporfin potassium (TOOKAD® Soluble) | Pd | EMA approved | 753 | EU | Prostate | |
| TLD-1433 | Ru | Phase 2 | 520 | Canada | Bladder, brain | |
| Motexafin lutetium (Antrin®) | Lu | Terminated | 732 | USA | Breast, prostate | |
| Rostaporfin (Purlytin®) | Sn | Phase 2/3 | 664 | USA | Breast, bile duct, ovarian, colon |
aData from clinicaltrials.gov.